SLC16A1 and cancer: Recently, MCT1 inhibition has been recognized as an attractive therapeutic strategy against cancers since the blockade of lactate transport was found to affect tumor growth either through the accumulation of intracellular lactate formed during anaerobic glycolysis or the restriction of lactate uptake and, thus, the fueling of cell oxidative phosphorylation [30].